BIOPHARMA
By
Could Excelsior Sciences’ $95M AI Surge Redefine How Fast Small-Molecule Drugs Reach the Market?
Key Highlights • $95M funding round positions Excelsior to compress multi-month chemistry cycles into weeks, reshaping competitive timelines…
Will Novartis’s $12 Billion Avidity Deal Ignite a New Era of AI-Powered RNA Therapeutics and Transform Rare-Disease Innovation?
Key Insights:• Novartis AG acquires Avidity Biosciences for $12 billion (USD 72 per share) — the company’s largest…
Can Eli Lilly and NVIDIA’s AI Supercomputer Redefine Drug Discovery Timelines and Ignite a $40 Billion AI-Biopharma Revolution?
Key Insights:• Lilly builds one of pharma’s first NVIDIA-powered DGX SuperPODs, training AI on millions of experiments to…
Could the Algen Biotechnologies – AstraZeneca $555 Million AI-Driven Drug-Discovery Pact Redefine How Immunology Therapies Are Developed?
Key Highlights / Executive Take-aways: Strategic Significance of the PartnershipThe alliance between Algen Biotechnologies and AstraZeneca marks a…
How Is Senhwa Biosciences Using AI and Strategic Collaborations to Shape the Next Generation of Immuno-Oncology?
TAIPEI and SAN DIEGO — Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on first-in-class therapies for oncology,…
Will the European Commission’s New Health Policy Package Accelerate Biotech, AI, and Medical Device Innovation?
The European Commission has unveiled a new health policy package to strengthen innovation, competitiveness, and resilience across the…
